Cost Utility Analysis of Infliixmab and Adalimumab Compared with Conventional Therapy in Patients with Crohn Disease in the Islamic Republic of Iran
Abstract
Authors
P Zaboli S Nikfar A Kebriaeezadeh R Malekzadeh A Akbari Sari A Sima M Abdollahi S Mirzaei M Sharafkhah E Rohani